The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | CAR-T therapy options for multiple myeloma
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the range of immunotherapeutics against multiple myeloma, including the first FDA-approved BCMA targeting CAR-T therapy ide-cel (idecabtagene vicleucel), proven from the KarMMa trial (NCT03361748), with a median overall survival of 2 years. An upcoming therapeutic to be reviewed by FDA is cilta-cel (ciltacabtagene autoleucel), which is being evaluated as part of the CARTITUDE-1 trial (NCT03548207), showing an overall response rate of 98%. Both drugs aim to be delivered in earlier settings to improve efficacy. Dr Lin explains that many studies are looking at ways to improve CAR-T functions, such as longer therapeutic duration and faster manufacturing. Despite the many options for patients, it is important to view this data with longer follow-up times to compare the progression-free survival between the therapeutic options. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
